A HER2+ve breast cancer diagnosis can feel devastating. But with modern breakthroughs in targeted therapies, thousands of women now complete treatment and go on to live healthy, fulfilling lives. Yet, one concern often lingers in the minds of survivors: “Will the cancer come back?”
That’s where NERLYNX® (neratinib) steps in—as a powerful next step designed to reduce the risk of breast cancer recurrence after standard therapy.
What Is NERLYNX and How Does It Work?
NERLYNX is an oral targeted therapy prescribed after completing HER2-directed treatment like trastuzumab (Herceptin). It belongs to a class of medicines known as tyrosine kinase inhibitors (TKIs), which help to block HER2 signaling—a key driver in HER2-positive breast cancer cell growth.
Approved by:
- U.S. FDA (2017)
- European Medicines Agency (EMA) (2018)
Indication:
- Extended adjuvant treatment in early-stage HER2-positive breast cancer, especially for hormone receptor-positive women.
Form:
Oral tablets, taken once daily for 12 months.
NERLYNX in Clinical Trials: Real Data That Matters
In the landmark ExteNET Phase III clinical trial, 2,840 women who had finished one year of trastuzumab were given NERLYNX.
Key Results from the ExteNET Study:
• 💪 34% lower risk of invasive disease recurrence
• 💡 Greatest benefit seen in hormone receptor-positive patients
• 🧠 Lower risk of distant metastases—including in the brain—over 5 years
Source: The Lancet Oncology, 2016
Real Patient Experience: Meena’s Journey from Uncertainty to Confidence:
Meena, a 45-year-old mother from Bangalore, completed surgery, chemotherapy, and one year of trastuzumab. Her doctor recommended NERLYNX due to her HER2+ and hormone receptor-positive profile.
Though she experienced mild diarrhoea at the start, it was well-managed with supportive medication. She completed her full 12-month course—and remains cancer-free three years later.
Who Should Consider NERLYNX?
NERLYNX may be suitable for patients who:
- Have early-stage HER2-positive breast cancer
- Completed trastuzumab within the past 12 months
- Are hormone receptor-positive
- Have node-positive disease or large tumors—high-risk profiles for recurrence
What are the Side Effects—and How to Manage Them?
The most common side effect is diarrhea, especially during the first few weeks of treatment. However, early and proactive management makes a big difference.
Common Side Effects:
- Diarrhea (~93%, but only ~40% severe)
- Nausea
- Abdominal pain
- Fatigue
- Vomiting
Tip: Oncologists usually recommend starting loperamide (Imodium) from Day 1 to help control this.
Is NERLYNX AvaiIs NERLYNX Available in India?
Currently, NERLYNX is not commercially available in Indian pharmacies. However, patients can access it legally and ethically through the Named Patient Program (NPP)—a government-permitted import mechanism for unapproved medications in special cases.
How MitoGENE Supports You: Safe, Legal Access to NERLYNX
At MitoGENE, we specialize in helping Indian patients access critical therapies not available locally.
We provide:
- 📄 End-to-end support with regulatory documentation
- 🤝 Coordination with your treating doctor
- 🚚 Legal import and cold-chain delivery of NERLYNX to your city
- 🔒 Full compliance with Indian laws and patient safety standards
A Story of Access: Anita’s Path to Treatment
Anita, 39, from Mumbai, needed NERLYNX after completing her HER2+ breast cancer treatment. Local pharmacies couldn’t help, but through MitoGENE’s Named Patient Program, Anita’s medicine was safely imported from Europe, delivered with all clearances—and her treatment started right on time.
Final Thoughts: Taking the Next Step After HER2+ Breast Cancer
If you or a loved one has completed treatment for HER2-positive breast cancer and you worry about recurrence, NERLYNX could offer peace of mind. While not yet available off the shelf in India, MitoGENE ensures patients can access it safely, legally, and reliably.
Talk to your oncologist today. And if NERLYNX is right for you, we’re here to walk the journey with you—step by step.
Need Help Accessing NERLYNX in India?
Contact MitoGENE today for personalized assistance and regulatory support.
Mobile / Whatsapp: +91-9944424386, +91-9941034386 | Email: info@mitogene.org
Disclaimer: This information is based on open sources and does not replace medical advice. Always consult your treating doctor before starting any treatment. MitoGENE facilitates access under Indian regulations but does not prescribe or promote medicines.
Test comment
test comment